Autoimmune Gastrointestinal Dysmotility
Autoimmune gastrointestinal dysmotility (AGID) is a complex disorder characterized by impaired gut motility due to autoimmune dysfunction. Our company is dedicated to pushing the boundaries of research and innovation in AGID diagnostics, therapies, and animal models. Through our comprehensive services, we aim to provide effective solutions to pharmaceutical companies worldwide.
Overview of Autoimmune Gastrointestinal Dysmotility
Autoimmune gastrointestinal dysmotility refers to a disorder in which the immune system mistakenly targets and attacks the components of the gastrointestinal (GI) tract, leading to disrupted gut motility. This condition can affect various segments of the GI tract, including the esophagus, stomach, small intestine, and colon. Research has shown that autoantibodies targeting neuronal antigens play a crucial role in disrupting gut motility. These autoantibodies, including those against anti-gAChR, interfere with the normal functioning of neurotransmitters and receptors involved in gut motility regulation. Furthermore, humoral and cellular immune responses contribute to the development of AGID.
Fig.1 Overview of autoimmune gastrointestinal dysmotility (AGID). (Nakane S., et al., 2021)
Drug Discovery and Development for Autoimmune Gastrointestinal Dysmotility
Immunotherapy holds promise in inhibiting the misregulation of the immune response during the acute phase of AGID. Intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIg), and plasmapheresis (PP) are considered safe and appropriate therapies. Combination immunomodulatory therapies, such as combining prednisolone with PP or IVIg, have proven effective in some intractable cases. Alternative therapeutic regimens, including octreotide, rituximab, and cyclophosphamide, have also shown success in specific instances. The management of AGID depends on the underlying etiology, with paraneoplastic AGID requiring tumor therapeutics in addition to symptomatic management.
Our company is committed to developing effective therapies for AGID that target the underlying autoimmune dysfunction. Our team of experts utilizes state-of-the-art technologies and in-depth knowledge of AGID pathogenesis to identify therapeutic targets and design innovative therapy solutions. Below are the different therapeutic development platforms we showcase, and you can click on the links to learn more.
Our Services
To support the development of better therapies, our company provides innovative and accurate AGID diagnostics development services. Through extensive research and collaboration with leading experts, we strive to identify novel biomarkers, develop advanced imaging techniques, and implement cutting-edge molecular assays for AGID diagnostics development. We also offer comprehensive preclinical research services for AGID, including efficacy and safety assessments of potential therapeutic interventions.
AGID Immunization Animal Models
At our company, we offer AGID immunization animal model development services by using live nicotinic acetylcholine receptor alpha 3 (AChRα3) expressing xenogeneic cells. Mice actively immunized with these cells exhibit severe hypomotility and reduced enteric nicotinic AChRα3 levels, without neuronal cell loss in the enteric ganglia.
AAG Immunization Rabbit Models
AGID is frequently detected in individuals diagnosed with autoimmune autonomic ganglionopathy (AAG). We offer AAG immunization Rabbit model development services. These immunized rabbits produce gAChR autoantibodies and develop autonomic failure, including gastroparesis and weight loss.
By isolating and culturing enteric neurons, immune cells, and other relevant cell types, we can investigate the impact of autoantibodies, cytokines, and other factors on gastrointestinal dysmotility. To mimic the complex cellular interactions that occur in AGID, we have developed co-culture models using primary cells.
Our researchers have successfully developed intestinal organoids derived from human pluripotent stem cells or intestinal tissue-specific stem cells. These organoids comprise multiple cell types, including enteric neurons, epithelial cells, and immune cells, and recapitulate the cellular diversity and architecture of the gastrointestinal tract.
Through rigorous experimentation and data analysis, we provide valuable insights into the efficacy, pharmacokinetics, and toxicity profiles of novel drug candidates. In addition to the aforementioned services and models, we also provide customized solutions and develop disease models that cater specifically to your unique needs. If our services have piqued your interest, please do not hesitate to contact us.
Reference
- Nakane S., et al. "Autoimmune gastrointestinal dysmotility: the interface between clinical immunology and neurogastroenterology." Immunological Medicine 44.2 (2021): 74-85.